Pharma BD Deal Intelligence

Cephalon Inc. / Anesta Corp.

2000 · Acquisition/Merger · $444M · Complete

Cephalon acquired Anesta in an all-share deal worth ~$444M ($31.45/share). Brought worldwide rights to Actiq (OTFC fentanyl) for breakthrough cancer pain — Cephalon's first marketed in-house product alongside Provigil. Closed October 2000.

Did it work? Outcome assessment

Assessment window: 5yr post-close.

Key facts

• Announced Jul 17, 2000
• Closed Oct 13, 2000
• Deal value $444M
• Deal type Acquisition/Merger
• Therapeutic area Breakthrough cancer pain
• Indications Breakthrough cancer pain
• Key assets Actiq (oral transmucosal fentanyl citrate)
• Mechanism Mu-opioid receptor agonist

← Browse all deals  ·  How we score deals